




# Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



February 1, 1996  
Volume 56 • Number 3  
PP. 429-661  
ISSN 0008-5472 • CNREA 8



**LATE-BREAKING RESEARCH SESSION  
AT THE AACR ANNUAL MEETING  
Tuesday, April 23, 1996**

*One hour has been set aside for the presentation of about 4 definitive reports of highly significant and timely findings in the field. Criteria for the selection of these presentations and instructions for submission of abstracts are as follows:*

**INSTRUCTIONS FOR SUBMISSION OF LATE-BREAKING ABSTRACTS**

1. The work to be presented must be of major novelty and significance, *e.g.*, the characterization of a new gene in familial cancer, and should not have been previously published in a peer-reviewed scientific journal or presented at a national meeting.
2. The abstract must be sponsored by an AACR member in good standing (dues paid for 1996).
3. Each member in good standing may sponsor only **one** abstract for this session whether or not he or she sponsored an abstract last December for the regular annual meeting program. If an associate member is the **sponsor**, the abstract must also be **endorsed** by an active or corresponding member in good standing. In this case, the **endorser** does **not** forfeit the opportunity to **sponsor** a late-breaking abstract.
4. Abstracts must be typed on **one** side of **one** sheet of white paper.
5. All text on the page must fit within an area 6 1/2" wide and 9" high (16.5 cm X 22.9 cm) with margins of at least 1" (2.5 cm) on the top, bottom, and sides of the page.
6. Each abstract must be accompanied by a covering letter from the sponsor explaining why the work is novel and significant enough to be considered for this late-breaking research session and certifying that the findings became available **after** the annual meeting abstract deadline of December 1, 1995. This letter must contain the sponsor's complete mailing address, FAX number, and Email address (if available) so that we can communicate the scheduling decision of the Program Committee.
7. Abstracts and covering letters must be received in the AACR Office by 5:00 p.m. Eastern Time on **March 15, 1996**. FAX transmissions are **not** acceptable. Carrying envelopes should be clearly marked "Late-Breaking Abstract," and should be addressed to American Association for Cancer Research, Public Ledger Building, Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. If you wish to receive acknowledgment of receipt of your abstract, enclose a self-addressed post card with appropriate postage affixed. Accepted abstracts will not be published since they will be received after the *Proceedings of the American Association for Cancer Research* has been printed; however, they will be distributed at the session in Washington.
8. A special subcommittee of the Program Committee appointed by President Joseph R. Bertino will select the papers to be presented. Presenters of accepted papers will be notified via FAX no later than **March 29, 1996**.

## AMERICAN ASSOCIATION FOR CANCER RESEARCH

The American Association for Cancer Research (AACR) is a professional society of over 10,600 scientists and physicians involved in all aspects of basic, clinical, and translational cancer research. Members of the AACR enjoy

- subscriptions to *Cancer Research*, *Cell Growth & Differentiation (CG&D)*, *Cancer Epidemiology, Biomarkers & Prevention*, and *Clinical Cancer Research* at reduced member rates
- reduced registration rates at the AACR Annual Meeting, Special Conferences, and International Meetings
- Employment Register, Directory of Members, public education activities, and many other benefits

Special programs to provide enhanced career development opportunities for minority scientists include

- **Session on Career Development at Annual Meeting**
- **Mentorship Program**
- **Travel Awards to Scientific Meetings**

### American Association for Cancer Research

Public Ledger Building, Suite 816  
150 S. Independence Mall West  
Philadelphia, PA 19106-3483  
Telephone: (215) 440-9300

FAX: (215) 440-9313 / E-Mail: [aacr@aol.com](mailto:aacr@aol.com)

## YALE UNIVERSITY

The Yale University Comprehensive Cancer Center under Dr. Vincent DeVita, Jr., and the Medical Oncology Section of the Yale University School of Medicine under the new leadership of Dr. Albert Deisseroth, have developed faculty positions at the Assistant and Associate Professor levels for clinician scientists and clinical investigators interested in establishing new directions in therapy for any and all organ sites in medical oncology. With a network of 14 referring hospitals in Connecticut from which to accrue patients, Yale's heritage of excellence in radiation therapy, surgical oncology, and molecular pharmacology, combined with world class strengths in signal transduction, structural biology, genetics, and immunology, provide an environment in which the boldest and most exciting initiatives in therapy can be aggressively pursued. Please send C.V. and three letters of reference to: Mrs. Jacqueline McKim, Department of Internal Medicine, Yale University School of Medicine, 135 College Street, 2nd Floor, New Haven, CT 06510-2483, by 3/1/96.

*Yale is an Affirmative Action/Equal Opportunity Employer. Women and members of minority groups are encouraged to apply.*

THE SURGERY BRANCH, NATIONAL CANCER INSTITUTE, NIH, IS SEEKING PATIENTS FOR ONGOING CLINICAL TREATMENT PROGRAMS.

PATIENTS WITH THE FOLLOWING MALIGNANCIES ARE BEING TREATED UNDER COMBINED MODALITY OR INNOVATIVE IMMUNOTHERAPY PROGRAMS:

- METASTATIC MELANOMA AND KIDNEY CANCER •
- STAGE II OR LOCALLY ADVANCED BREAST CANCER •
- METASTATIC COLORECTAL CANCER TO THE LIVER •
- LOCOREGIONAL GASTRIC OR PANCREATIC CANCER •
- MESOTHELIOMA, PULMONARY METASTASES, STAGE IIIA, B LUNG CANCER  
OR ESOPHAGEAL CANCER •
- LOCALIZED SOFT TISSUE SARCOMAS •
- PERITONEAL CARCINOMATOSIS •

**NATIONAL  
CANCER  
INSTITUTE**

CARE FOR ALL PATIENTS IS PROVIDED AT THE CLINICAL CENTER, NIH, BETHESDA, MARYLAND.

FOR MORE INFORMATION ON CANCER PROGRAMS, PLEASE CALL  
(301) 496-1533

*A PUBLIC SERVICE ANNOUNCEMENT COURTESY OF THIS PUBLICATION*



# 87th AACR Annual Meeting Preliminary Program

(Names of session chairpersons are underlined.)

## SATURDAY, APRIL 20, 1996

- 11:00 a.m.-8:00 p.m. Registration**
- 12:00 noon-6:30 p.m. Educational Sessions**
- ED1** *Human Pharmacogenetics: Molecular Mechanisms and Clinical Relevance in Cancer Treatment*, William E. Evans, Denis M. Grant, Robert B. Diasio
- ED2** *Bench to Bedside: Opportunities and Pitfalls in the Discovery and Development of Cancer Therapies*, Robert L. Capizzi, Allen I. Oliff, Randall K. Johnson, Kenneth R. Harrap
- ED3** *The Cell Cycle*, Michael B. Kastan, William G. Kaelin, Jr., Chi Van Dang
- ED4** *Beyond the Human Genome Project: Technical Aspects of Genomic Characterization and Its Application to Cancer Research*, Glen A. Evans
- ED5** *Combinatorial Libraries*, Sydney E. Salmon
- ED6** *Transcriptional Regulatory Pathways and the Response to Cellular Stress*, Arnold B. Rabson, Carl Wu, Albert J. Fornace, Jr.
- 2:00 p.m.-6:00 p.m. Methods Workshops (Separate registration required)**
- WK1** *Quantitative Biology and Pharmacodynamics*, Robert C. Jackson, Robert L. Dedrick, Mark J. Ratain, William R. Greco
- WK2** *Animal Models: Transgenic and Knockout Mice in Cancer Investigations*, Terry Van Dyke
- 6:30 p.m.-8:00 p.m. Women in Cancer Research Guest Lecture Opening Reception**
- 8:00 p.m.-10:00 p.m. Opening Mixer**

- 1:00 p.m.-2:00 p.m. Controversy Session 2**  
*Have Preclinical Models In Studies of Drug Resistance Provided Accurate Predictions for Clinicians?*, Bruce A. Chabner, Susan E. Bates, Herbert M. Pinedo
- 1:00 p.m.-5:00 p.m. Poster Discussion Sessions**
- 1:00 p.m.-5:00 p.m. Poster Sessions**
- 1:45 p.m.-5:15 p.m. Minisymposia**
- 2:15 p.m.-5:15 p.m. Symposia**
- S1** *Tumor Suppressor Genes*, Bert Vogelstein, Yosef Shiloh, Todd Waldman, Alexander Kamb, Allan Bradley, Richard D. Klausner
- S2** *Ovarian Cancer: From the Laboratory to the Clinic*, Robert F. Ozols, Thomas C. Hamilton, Steven A. Narod, E.G. Elisabeth de Vries, David T. Curiel
- S3** *Apoptosis: Manipulating Programmed Cell Death in Cancer*, David E. Fisher, Hermann Steller, Stanley J. Korsmeyer, Douglas R. Green, Douglas K. Miller
- S4** *Monoclonal Antibodies: Clinical Effectiveness*, Ellen S. Vitetta, Mark Sliwkowski, Pamela A. Trail, Dana C. Matthews
- S5** *Genetic, Environmental, and Behavioral Factors in Cancer Risk*. Organized by the AACR Minority Issues Committee. Lucile L. Adams-Campbell and Francis Ali-Osman, Caryn E. Lerman, John S. Kovach, Margaret R. Spitz, George E. Bonney, Hie-Won L. Hann, Ronald A. Morton, Jr.
- 5:30 p.m.-6:30 p.m. Joseph H. Burchenal/AACR Clinical Research Award Lecture**
- 6:30 p.m.-9:00 p.m. Minority Issues Careers Symposium**
- 8:00 p.m.-10:30 p.m. Annual Reception**

## SUNDAY, APRIL 21, 1996

- 7:00 a.m.-4:00 p.m. Registration**
- 7:00 a.m.-8:00 a.m. Sunrise Sessions**
- SUN1** Diane F. Birt: Mechanisms of Dietary Prevention of Cancer
- SUN2** William S. Dalton: Challenges in Bone Marrow Transplantation
- SUN3** Ronald B. Herberman: Natural Killer Cells
- SUN4** Rakesh K. Jain: Tumor Pathophysiology: Role in Delivery of Molecules, Particles, and Cells
- SUN5** Lovell A. Jones: Estrogens and Breast Cancer
- SUN6** Stanley J. Korsmeyer: *Bcl* and Cell Death
- SUN7** Funmi I. Olopade: Chromosomal Deletions and Cancer: Recent Advances in Mapping Techniques
- 8:00 a.m.-12:00 noon Poster Discussion Sessions**
- 8:00 a.m.-12:00 noon Poster Sessions**
- 8:15 a.m.-11:45 a.m. Minisymposia**
- 8:15 a.m.-11:30 a.m. Plenary Session**  
*Twenty-fifth Anniversary of the National Cancer Act: Progress and Promise*, Joseph R. Bertino, Harold E. Varmus, Arnold J. Levine, Susan Band Horwitz, Paul Talalay, James F. Holland, Lloyd J. Old
- 11:45 a.m.-12:45 p.m. 35th Clowes Award Lecture: Robert A. Weinberg**
- 12:30 p.m.-5:00 p.m. Commercial Exhibit Show**
- 1:00 p.m.-2:00 p.m. Controversy Session 1**  
*Is Beta-Carotene Useful in Cancer Prevention?*, Wau Ki Hong, Frank L. Meyskens, Jr., E. Robert Greenberg

## MONDAY, APRIL 22, 1996

- 7:00 a.m.-4:00 p.m. Registration**
- 7:00 a.m.-8:00 a.m. Sunrise Sessions**
- SUN8** Peggy J. Farnham: Nuclear Oncogenes: Effects on Cell Cycle Regulation and Neoplastic Transformation
- SUN9** John Gribben: Quantitative PCR as a Tool to Detect Minimal Residual Disease in Lymphoma and Leukemia
- SUN10** Stephen S. Hecht: Chemoprevention of Cancers Associated with Tobacco Use
- SUN11** V. Craig Jordan: Antiestrogens
- SUN12** Philip Livingston: Specific Immunotherapy of Melanoma
- SUN13** John A. McLachlan: Environmental Carcinogens: Their Impact in Cancer
- SUN14** Daniel Medina: Mammary Carcinogenesis
- 7:00 a.m.-8:00 a.m. WICR Networking Session**
- 8:00 a.m.-11:00 a.m. Symposia**
- S6** *Steroid Hormones: Breast and Prostate Cancer*, Myles A. Brown, Donald P. McDonnell, Benita S. Katzenellenbogen, Roger L. Miesfeld, Norman M. Greenberg
- S7** *Matrix Metalloproteinases and Their Inhibitors*, Lynn M. Matrisian, Ruth J. Muschel, Motoharu Seiki, Yves DeClerck, Peter Brown
- S8** *Recent Developments in Gene Therapy*, Drew M. Pardoll, Inder M. Verma, Philip D. Greenberg, Arthur Bank
- S9** *Viral Mechanisms of Carcinogenesis*, Harald zur Hausen, David M. Livingston, William Robinson, Yuan Chang, Kathleen R. Cho
- 8:00 a.m.-12:00 noon Poster Discussion Sessions**
- 8:00 a.m.-12:00 noon Poster Sessions**
- 8:15 a.m.-11:45 a.m. Minisymposia**

10:00 a.m.-4:00 p.m. Commercial Exhibit Show  
 11:45 a.m.-12:45 p.m. Presidential Address: Joseph R. Bertino  
 1:00 p.m.-2:00 p.m. Fifth American Cancer Society Award  
 Lecture: Lee W. Wattenberg  
 1:00 p.m.-2:00 p.m. Controversy Session 3  
*Does Regional Chemotherapy Work?* David S. Alberts, Maurie Markman, Michael J. O'Connell  
 1:00 p.m.-5:00 p.m. Poster Discussion Sessions  
 1:00 p.m.-5:00 p.m. Poster Sessions  
 1:45 p.m.-5:15 p.m. Minisymposia  
 2:15 p.m.-5:15 p.m. Symposia  
 S10 *Cell Responses to DNA Damaging Agents*, Nathan A. Berger, Mark T. Muller, Joseph Avruch, George R. Stark, William F. Morgan  
 S11 *Drug Resistance: Transcriptional and Translational Mechanisms*, Kathleen W. Scotto, Jane Clifford Azizkhan, Jim A. Wright, Edward Chu, Ian D. Hickson  
 S12 *Melanoma as a Clinical Model*, Alan N. Houghton, Jane W. Fountain, Steven A. Rosenberg, Pierre van der Bruggen, John M. Kirkwood  
 S13 *Nutrition and Cancer*, Walter C. Willett, David J. Hunter, John D. Potter, Diane F. Birt, Frank L. Meyskens, Jr.  
 5:30 p.m.-6:00 p.m. Presentation by NCI Director: Richard D. Klausner  
 6:00 p.m.-7:00 p.m. Business Meeting

---

**TUESDAY, APRIL 23, 1996**

7:00 a.m.-4:00 p.m. Registration  
 7:00 a.m.-8:00 a.m. Sunrise Sessions  
 SUN15 **Robert L. Comis**: Lung Cancer: A Primer  
 SUN16 **Jerry D. Glickson**: NMR As a Prognosticator of Tumor Therapeutic Response  
 SUN18 **Susan Jaken**: Protein Kinase C in Cell Transformation  
 SUN18 **Jay A. Levy**: Immunologic Features of AIDS Pathogenesis  
 SUN19 **Yves G. Pommier**: DNA Topoisomerases and Their Inhibitors  
 SUN20 **Barrett J. Rollins**: Chemokines and Leukocyte-specific Chemotactic and Activating Factors  
 SUN21 **Stephen E. Sallan**: Childhood Leukemias: The Latest in Treatment  
 7:00 a.m.-8:00 a.m. NIH Grants Session  
 8:00 a.m.-11:00 a.m. Symposia  
 S14 *Endogenous DNA Damage: Detection and Biological Significance*, John M. Essigmann, Leona D. Samson, B. Singer, Lawrence J. Marnett, Lawrence A. Loeb  
 S15 *Targeting Growth Factor Receptors for Therapy*, John Mendelsohn, Thomas A. Waldmann, David W. Golde, Ira Pastan, Alexander Levitzki  
 S16 *Aberrant Transcription Factors and Malignancy*, Lorraine J. Gudas, A. Thomas Look, Anne Dejean, Christopher T. Denny, Terry H. Rabbitts  
 S17 *Thymidylate Synthase and Its Inhibitors*, Frank Maley, Carmen Allegra, Gary K. Smith, William R. Montfort, Bruce J. Dolnick  
 8:00 a.m.-12:00 noon Poster Discussion Sessions  
 8:00 a.m.-12:00 noon Poster Sessions  
 8:15 a.m.-11:45 a.m. Minisymposia  
 11:00 a.m.-5:00 p.m. Commercial Exhibit Show  
 11:45 a.m.-12:45 p.m. 20th Rosenthal Award Lecture: James O. Armitage  
 1:00 p.m.-2:00 p.m. Late-breaking Research Session  
 1:00 p.m.-5:00 p.m. Poster Discussion Sessions  
 1:00 p.m.-5:00 p.m. Poster Sessions

1:45 p.m.-5:15 p.m. Minisymposia  
 2:15 p.m.-5:15 p.m. Symposia  
 S18 *Cell Signaling*, Channing Der and Deborah Morrison, Ann Marie Pendergast, Melanie Cobb  
 S19 *Cancer Chemoprevention in Humans*, Thomas W. Kensler, Gary J. Kelloff, Michael N. Gould, Alberto F. Costa, Francis M. Giardiello  
 S20 *Neuroblastoma: Recent Advances in Biology and Treatment*, Garrett M. Brodeur, Susan L. Cohn, Robert C. Seeger, Nai-Kong V. Cheung, Katherine K. Matthay, Robert P. Castleberry  
 S21 *Telomerase, Cell Senescence, and Cancer*, Calvin B. Harley, J. Carl Barrett, Maria Blasco, Jerry W. Shay, Karen Prowse  
 4:45 p.m.-5:30 p.m. DeWitt Goodman Lecture: David J. Mangelsdorf  
 5:30 p.m.-6:30 p.m. 15th Rhoads Award Lecture: Carol W. Greider, *Telomerase Function and Regulation in Normal and Cancer Cells*  
 6:30 p.m.-8:00 p.m. WICR Business Meeting

---

**WEDNESDAY, APRIL 24, 1996**

7:00 a.m.-2:00 p.m. Registration  
 7:00 a.m.-8:00 a.m. Sunrise Sessions  
 SUN22 **Ernest C. Borden**: Interferons in Cancer  
 SUN23 **Richard A. Heyman**: Transcription Factors As Therapeutic Targets  
 SUN24 **Theodore S. Lawrence**: Radiation Sensitization  
 SUN25 **Eric K. Rowinsky**: Drugs Which Interact with Microtubules: An Update  
 SUN26 **Jeffrey Schlom**: Tumor Vaccines  
 SUN27 **Peter D. Senter**: Prodrugs for Cancer Chemotherapy  
 SUN28 **Martha R. Stampfer**: Culturing Normal and Neoplastically Transformed Human Epithelial Cells  
 8:00 a.m.-11:00 a.m. Symposia  
 S22 *Cell Adhesion Molecules and the Cytoskeleton*, Jun-Lin Guan and Rudolph L. Juliano, Thomas P. Stossel, Paul Polakis, Eva Ann Turley  
 S23 *Drug Metabolizing Enzymes in Cancer Prevention and Therapy*, Cecil B. Pickett, F. Peter Guengerich, Frank J. Gonzalez, Chung S. Yang  
 S24 *The Cell Cycle and Damage Response Pathways: Potential Targets for Therapy*, Stephen H. Friend, Frank McCormick, David Beach, James M. Roberts, Nick J. Dyson, Paul A. Marks  
 8:00 a.m.-12:00 noon Poster Discussion Sessions  
 8:00 a.m.-12:00 noon Poster Sessions  
 8:15 a.m.-11:45 a.m. Minisymposia  
 11:45 a.m.-12:45 p.m. 15th Cain Award Lecture: Kurt W. Kohn, *Beyond DNA Crosslinking*  
 1:00 p.m.-2:00 p.m. Controversy Session 4  
*Is p53/Rb Important for Therapeutic Outcome?*, William F. Benedict, Carlos Cordon-Cardo, David Sidransky  
 Controversy Session 5  
*Should Genetic Testing Be Done on Patients to Assess Cancer Risk?* Judy E. Garber  
 1:00 p.m.-5:00 p.m. Poster Discussion Sessions  
 1:00 p.m.-5:00 p.m. Poster Sessions  
 1:45 p.m.-5:15 p.m. Minisymposia  
 2:15 p.m.-5:15 p.m. Symposia  
 S25 *Tumor Angiogenesis*, Judah Folkman and Mark A. Goldberg, Webster K. Cavenee, Richard I. Weiner, Philip E. Thorpe, Elise C. Kohn  
 S26 *Genetic Predisposition to Cancer*, Mark H. Skolnick, Francis S. Collins, Richard D. Kolodner, William B. Isaacs, Sean Tavtigian

# COVER LEGEND



## Cancer Research



February 1, 1996  
Volume 56 • Number 3  
ISSN 0008-5472 • CRR A 8

The contributions of the Pezcoller Foundation to the fight against cancer represent an Italian commitment to the international efforts in this field. The Foundation was created in 1979 by Professor Alessio Pezcoller (1896–1993) (*left*), who was the chief surgeon of the S. Chiara Hospital in Trento and who gave a substantial portion of his estate to support the Foundation's activities. The Foundation was officially recognized in 1982 by a decree of the President of the Republic of Italy.

The main goal of this nonprofit Foundation is to recognize and provide for scientific progress on life-threatening diseases, with a special focus on cancer. To this end, every two years, the Pezcoller Foundation grants the prestigious Pezcoller Award, recognizing seminal contributions to basic biomedical research with an emphasis on oncology, and The Pezcoller Recognition for Dedication to Oncology, bestowed on outstanding leaders for their contributions to oncology in their community. Since 1989, the Foundation has also sponsored a series of annual symposia, which are focused on molecular mechanisms of control of normal and neoplastic cells, and which are aimed at promoting interactions among scientists from various parts of the world who have different expertise and are working on the cutting edge of the basic oncological sciences. In 1995, an annual series of advanced education seminars in oncology for Italian clinicians was initiated. Through these activities, the Foundation fulfills the mandate of its founder who once said that he made his personal wealth available to the Foundation "because it seems right that the money which came from the sick should return, albeit indirectly, to the sick."

The Pezcoller Award selection process is carried out by an international committee of experts and is managed by the European School of Oncology in Milan, Italy. In 1995, the award went to Paul Nurse, Imperial Cancer Research Fund (ICRF), London, United Kingdom, who was recognized for his seminal contributions to the understanding of the molecular mechanisms of the control of cell progression through the cell cycle.

Dr. Nurse (*right*) received his Ph.D. in Cell Biology/Biochemistry in 1973. Shortly after his degree, he obtained a research fellowship from the Royal Society and spent one year

at the Institute of Microbiology of the University of Bern, Switzerland. In 1974, he joined the Department of Zoology of the University of Edinburgh, where he stayed until 1980 and carried out fundamental research on the control of cell cycle in yeast. From 1980 to 1984, he was a Senior Research Fellow at the School of Biology, University of Sussex, and in 1984, he became Head of the Cell Cycle Control Laboratory at the ICRF. In 1987, he became a Research Professor at the University of Oxford, and in 1993, he was appointed Director of Research (Laboratories) and Head of the Cell Cycle Laboratory of the ICRF, a position he is currently holding. Many prestigious honors have been bestowed on Dr. Nurse, and he is a member of the Editorial Boards of several respected journals in the areas of molecular and cellular biology. He is the author of more than 130 publications which have made major contributions to progress in the understanding of the mechanisms of cell cycle control.

In 1975, Dr. Nurse genetically identified the protein kinase catalytic subunit  $p34^{cdc2}$  in yeast and determined that its function is required for cell cycle progression at the  $G_2/M$  boundary. This observation first pointed to the primary role of protein phosphorylation in cell cycle control. It also substantiated the existence of restriction points affecting cell cycle progression which had been previously proposed by others. Furthermore, this work provided the first evidence of the molecular mechanisms of cell cycle control and underscored the invaluable role of genetics in establishing the functional significance of specific gene products required for cell cycle progression. Later, Dr. Nurse verified a major role for  $p34^{cdc2}$  in mammalian  $G_2/M$  control, demonstrating the regulation of its activity through phosphorylation and discovering the basic mechanisms associated with the formation of biochemically active  $p34^{cdc2}$ . These pioneering discoveries established the standing and the regulation of action of a key cyclin-dependent kinase in the cell cycle and opened this field to investigations which have led, in relatively short order, to major advances in our increasingly rich understanding of cellular growth control.

The significance of Dr. Nurse's discoveries extends to a variety of biological processes. The work of his laboratory is directly linked to the molecular biology of cancer cells, which are, at least in part, the product of disordered cell replication and disarray in the control of certain key events in the cell cycle. Indeed, fundamental discoveries of the Nurse group which speak to how eukaryotic cells, and mammalian cells in particular, maintain the ability to replicate under control have already begun to have an impact on the thinking of those dedicated to creating new rational therapeutic strategies for cancer. Furthermore, the high and continuous rate of accrual of new and powerful information from the Nurse laboratory on this general subject cannot but bring added light to bear upon the detailed molecular mechanisms which underlie the control of  $G_1/S$  and  $G_2/M$  passage, as well as progression through and out of S phase. Intensive research on those protein-protein interactions which guide cells through these various checkpoints and control points has already begun to elucidate the molecular events that are defective in cancer cells and that contribute to their inability to maintain normal cell cycle regulation.

We thank Giorgio Pederzoli, Giuseppe Bernardi, and Enrico Mihich for their assistance in providing the information and photographs for this cover feature.

Sidney Weinhouse